Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734571 | SCV000862723 | uncertain significance | not provided | 2018-07-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001417396 | SCV001619596 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-08-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002406672 | SCV002723384 | uncertain significance | Cardiovascular phenotype | 2021-08-04 | criteria provided, single submitter | clinical testing | The c.1865C>T (p.T622M) alteration is located in exon 14 (coding exon 14) of the JAG1 gene. This alteration results from a C to T substitution at nucleotide position 1865, causing the threonine (T) at amino acid position 622 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |